Apogee Therapeutics Inc. (APGE)
NASDAQ: APGE
· Real-Time Price · USD
39.26
0.01 (0.03%)
At close: May 01, 2025, 3:59 PM
39.20
-0.15%
Pre-market: May 02, 2025, 06:20 AM EDT
Company Description
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications.
The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.
Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD.
The company was founded in 2022 and is based in Waltham, Massachusetts.
Apogee Therapeutics Inc.
| Country | United States |
| IPO Date | Jul 14, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 196 |
| CEO | Dr. Michael Thomas Henderson M.D. |
Contact Details
Address: 221 Crescent Street Waltham, Massachusetts United States | |
| Website | https://www.apogeetherapeutics.com |
Stock Details
| Ticker Symbol | APGE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001974640 |
| CUSIP Number | 432705309 |
| ISIN Number | US4327053090 |
| Employer ID | 93-4958665 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Michael Thomas Henderson M.D. | Chief Executive Officer & Director |
| Jane Pritchett V. Henderson | Chief Financial Officer |
| Matthew Batters J.D. | Chief Legal Officer & Corporate Secretary |
| Dr. Carl Linden Dambkowski M.D. | Chief Medical Officer |
| Dr. Drew Badger Ph.D. | Senior Vice President and Head of Regulatory Affairs & Toxicology |
| Dr. Mehrak Kiankarimi Ph.D. | Senior Vice President of Program & Portfolio |
| Dr. Rebecca Dabora Ph.D. | Chief Development Officer |
| Monica Forbes | Senior Vice President of Finance |
| Noel Kurdi | Vice President of Investor Relations |
| Wendy Aspden-Curran | Senior Vice President of Clinical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 29, 2025 | ARS | Filing |
| Apr 29, 2025 | DEFA14A | Filing |
| Apr 29, 2025 | DEF 14A | Filing |
| Apr 04, 2025 | 4 | Filing |
| Mar 11, 2025 | 8-K | Current Report |
| Mar 07, 2025 | 4 | Filing |
| Mar 07, 2025 | 4 | Filing |
| Mar 03, 2025 | 8-K | Current Report |
| Mar 03, 2025 | S-8 | Filing |
| Mar 03, 2025 | 10-K | Annual Report |